Core Viewpoint - Polyrizon Ltd. has announced positive in-vitro results for its PL-16 Viral Blocker, demonstrating strong protection against H1N1 influenza through a reversible physical barrier mechanism [1][4]. Group 1: Product Efficacy - The PL-16 formulation effectively blocked infection from multiple respiratory viruses, including H1N1, maintaining high cell viability and preventing viral-induced cytopathic effects [2][4]. - The formulation exhibited robust protection without cytotoxicity, confirming both safety and efficacy [2][4]. Group 2: Mechanism of Action - The antiviral effect is due to a reversible physical interaction rather than irreversible viral inactivation, as viruses regained infectivity after the formulation was removed [3][4]. - The formulation acts as a temporary physical barrier that prevents viral particles from entering host cells [3][4]. Group 3: Future Development - Polyrizon plans to advance the PL-16 formulation through clinical studies, subject to regulatory approvals, reinforcing its commitment to innovative respiratory protection solutions [4][5]. - The company is also developing additional aspects of its Capture and Contain hydrogel technology for enhanced nasal delivery of drugs [6].